Form 4: VolitionRx CEO Cameron John Reynolds Acquires 20,000 Shares

Cameron John Reynolds, CEO of VolitionRx Ltd, reports the acquisition of 20,000 shares of common stock at a price of $0.4365 per share.

Summary

• Cameron John Reynolds, the President and CEO of VolitionRx Ltd, filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on May 19, 2025.
• Mr. Reynolds acquired 20,000 shares of VolitionRx Ltd common stock at a price of $0.4365 per share.
• Following the transaction, Mr. Reynolds directly owns 2,319,222 shares.
• He also indirectly owns 1,007,718 shares through Concord International, Inc., where he is the majority shareholder.
• Additionally, he indirectly owns 34,076 shares through his spouse.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is generally a positive sign, but the impact is limited without additional context about the company's overall performance.

Positives

• The CEO's purchase of shares could be interpreted as a sign of confidence in the company's future prospects.

Industry Context

Insider buying is often viewed positively by investors, as it suggests that a company's leadership believes the stock is undervalued and has potential for future growth. However, it's important to consider the overall context of the company's performance and industry trends before making investment decisions based solely on insider activity.

Stakeholder Impact

• Shareholders may view the CEO's purchase as a positive signal.
• The purchase has a limited impact on employees, customers, suppliers, and creditors.

Key Dates

Keywords

Form 4, VNRX, VolitionRx Ltd, Cameron John Reynolds, Insider Trading, Beneficial Ownership, SEC Filing, Stock Acquisition